ClinicalTrials.gg
Not yet recruitingNCT07656545Updated Jun 18, 2026

Early Intervention to Prevent Development of PTSD in Burn Survivors and Their Caregivers

An interventional study of Promotion of Emotional Disclosure for Burns (PoED-B) and minimally Enhanced Usual Care control (mEUC) in Posttraumatic Stress Disorder, Burns and Traumatic Injury, sponsored by University of Southern California. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by University of Southern California · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this clinical trial is to adapt and test a brief patient-caregiver early intervention designed to reduce posttraumatic stress symptoms in hospitalized burn patients and their caregivers. This intervention is a brief, 4-session cognitive-behavioral intervention designed for burn patients and their loved one to complete together, during and after hospitalization. The intervention targets relational communication and functioning through reduction of invalidating, negative statements and avoidant coping by teaching patients and their loved ones to engage in adaptive natural disclosures, supportive responses, and approach coping after the burn trauma. The intervention uses evidence-based psychotherapy techniques, including psychoeducation, motivational interviewing, and skills coaching. The clinical trial will occur in two sequential phases. In the first phase of the study (case series), the intervention will be provided to two burn patient-caregiver dyads (four adults) to pilot test the intervention, seek patient and provider feedback, and refine the intervention. All four adults will receive the intervention. In the second phase of the study, the randomized controlled trial (RCT) phase, investigators will enroll 20 more burn patient-caregiver dyads (40 more adults) who will be randomly assigned (like the flip of a coin) at the dyad level to receive the intervention or a burn survivor-only minimally enhanced usual care psychoeducation control condition (mEUC). The goals of the RCT phase are to study whether the intervention is acceptable to patients, feasible to conduct, and whether the intervention improves burn survivor-caregiver healthy relationship communication about difficult events and treatment outcomes compared to mEUC.

02

Conditions studied

  • Posttraumatic Stress Disorder
  • Burns
  • Traumatic Injury
  • Acute Stress Disorder
  • Trauma and Stressor Related Disorders
  • Trauma and Stress Related Disorders
  • Stress Disorder
  • Stress Disorders, Post-Traumatic
  • Stress Disorders, Traumatic
  • Stress Disorders, Traumatic, Acute
  • Relationship, Social
03

In context

Stress Disorders, Post-Traumatic

2,682 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 601 are open to participants now.

This study's planned enrollment of 44 is below the median of 69 across 2,196 interventional studies indexed under Stress Disorders, Post-Traumatic.

Browse Stress Disorders, Post-Traumatic studies →

Lead sponsor

University of Southern California is the lead sponsor of 791 studies on the registry; 136 are open to participants now.

Of its 70 completed or terminated interventional studies of FDA-regulated products, 32 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Alert, oriented, \& not withdrawing from substance at time of screening
  • Can read and write in English
  • Hospitalized within 10 days of burn injury
  • Anticipated discharge \<=4 weeks
  • Have an email, mailing address, and at least 1 smart device for telehealth sessions
  • PTSD risk score of 2 or greater (patient-only)
  • Willing to attend therapy sessions with a loved one

Exclusion criteria

Exclusion Criteria:

  • Currently incarcerated or in police custody
  • > 10 days post-burn
  • Lifetime diagnosis of primary psychosis or intellectual disability
  • Ongoing reported domestic violence in the dyad
  • Unstable bipolar disorder, severe substance use disorder, or acute suicidality with imminent intent that does not remit within 10 days of burn-injury
  • Inflammation Confounds (patient-only) of > 40, metabolic syndrome, admission of >= 6.5%
  • Currently receiving couples therapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Promotion of Emotional Disclosure for Burns (PoED-B)

    Participants randomized into this arm will receive Promotion of Emotional Disclosure for Burns (PoED-B), a cognitive behavioral therapy intervention designed for burn survivors and a loved one of their choosing to complete together. The standard treatment length will be 4 sessions, however participants and providers may agree to additional sessions as warranted.

    Behavioral: Promotion of Emotional Disclosure for Burns (PoED-B)

  • Active comparator
    minimally Enhanced Usual Care control (mEUC)

    Participants randomized into this arm will receive a minimally enhanced version of usual burn care. This will include one, 30-minute supportive therapy session focused on psychoeducation about the potential psychological impact of burn injury and hospitalization and referral to outpatient resources, if wanted.

    Behavioral: minimally Enhanced Usual Care control (mEUC)

Interventions

  • BehavioralPromotion of Emotional Disclosure for Burns (PoED-B)

    PoED-B is a dyadic treatment where both patient and identified informal caregiver participate. PoED-B targets reducing disclosure-constraining behaviors (e.g., invalidating, negative statements) using psychoeducation, motivational interviewing, and skills training. The goal is to encourage the patient-caregiver dyad to engage in natural disclosures, supportive responses, and approach coping after the burn trauma to facilitate emotional processing. It is four sessions long. Delivery format takes into account stakeholder feedback, considering overall burden during acute hospitalization and the transition to outpatient care. Sessions one and two are 30 minutes and one week apart. Sessions three and four are 50 minutes long and two weeks apart. Session one must occur during hospitalization. Sessions 2-4 can be completed via video/telehealth if the patient is discharged during the treatment course.

  • Behavioralminimally Enhanced Usual Care control (mEUC)

    mEUC is an individually-administered psychoeducation control for burn patients modeled after minimally enhanced care in acute care surgery units. In one 30-minute session, the therapist reviews with the participant a standardized psychoeducation handout on common psychological reactions after burn injury, giving them time to ask questions or express concerns within a supportive therapy framework. Then, the participant is given the handout, which also includes self-help skills. After study completion, participants will be given referrals for outpatient mental health services.

06

What researchers measure

Primary outcomes

  1. Social Constraints Scale

    The Social Constraints Scale is a self-report scale administered to both the patient and caregiver. It is designed to assess perceptions of negative reactions to trauma-disclosures. The scale contains 15 items, and each item is scored on a four-point scale ranging from 1 (never) to 4 (often) with total scores ranging from 15 to 60. A higher score indicates a higher frequency of experiencing social constraints.

    Time frame: Before treatment, immediately after ending treatment, 6-week follow-up

  2. Feasibility of Recruitment

    Proportion of participants who agree to participate from the total number of those that are eligible and approached.

    Time frame: baseline

  3. Feasibility of Data Collection

    Proportion of participants who completed each and all assessment timepoints

    Time frame: From enrollment to the end of study assessments at 6-weeks posttreament

  4. Acceptability: Satisfaction with Treatment

    Client Satisfaction Questionnaire (CSQ) - Self-Report - The CSQ has 8 items assessing client satisfaction with the treatment they have received. Total scores range from 8-32; higher scores indicate greater client satisfaction/treatment acceptability. This measure will be completed by both patients and their loved ones.

    Time frame: Immediately after ending treatment

  5. Acceptabilitly: Retention

    Proportion of enrolled dyads who completed at least 3 out of 4 PoED sessions.

    Time frame: Immediately after ending treatment

  6. Acceptability: Global Improvement Rating

    Proportion of participants who report overall improvement on the Global Rating of Change Scale

    Time frame: Immediately after ending treatment

Secondary outcomes

  1. PTSD Checklist for DSM-5 (PCL-5)

    The PTSD Checklist for DSM-5 is a 20 item self-report measure assessing PTSD symptom severity. Total scores range from 0-80 with higher scores indicating more severe PTSD symptoms.

    Time frame: Pretreatment, Immediately after ending treatment, 6-week follow-up

  2. Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)

    The Clinician-Administered PTSD Scale for DSM-5 is a structured interview measure of PTSD symptom severity (frequency and intensity) in the past month. Scores can range from 0-80, with higher scores indicating worse symptom severity. Only burn patients will complete this measure, not caregivers.

    Time frame: Immediately after ending treatment, 6-week follow-up

  3. Hospital Anxiety and Depression Scale (HADS)

    The Hospital Anxiety and Depression Scale is a 14-item self-report measure of anxiety and depression symptoms that was designed for the hospital environment. Each subscale has 7-items answered on a 4-point scale ranging from 0 to 3, yielding a maximum possible score of 21 for each subscale. Higher scores indicate worse symptoms.

    Time frame: Pretreatment, immediately after ending treatment, 6-week follow-up

  4. MINI Montreal International Neuropsychiatric Interview v. 7.0.2 (MINI)

    The MINI is a brief (\~15 minutes) structured psychodiagnostic interview for assessing DSM-5 disorders.

    Time frame: Pretreatment, immediately after ending treatment, 6-week follow-up

  5. Dyadic Relationship Scale (DRS)

    The Dyadic Relationship Scale is a self-report survey measuring dyadic strain and positive dyadic interaction specific to patient's health. There is a 10-item patient-version and 11-item caregiver version. Dyadic strain subscale scores range from 0-12 (patient version) and 0-15 (caregiver version). Positive dyadic interaction subscale scores range from 0-18. Higher scores on each of these scales indicate higher levels of strain and positive interaction, respectively.

    Time frame: Pretreatment, immediately after ending treatment, 6-week follow-up

  6. Significant Other's Responses to Trauma Scale (SORTS)

    The Significant Other's Responses to Trauma Scale is a 14-item self-report measure assessing frequency \& intensity of caregiver PTSD accommodation behaviors. Total scores can range from 0-112 with higher scores indicating greater accommodation.

    Time frame: Pretreatment, immediately after ending treatment, 6-week follow-up

07

Study locations

1 site
  • University of Southern California, Keck School of Medicine & Los Angeles General Medical Center
    Los Angeles, California 90033, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified demographic and raw quantitative data will be deposited into the NIMH Data Archive (NDA). All data will be de-identified prior to receipt by the repository. Data will be de-identified pursuant to the HIPAA Privacy Rule, 45 CFR § 164.514(b). A brief study protocol will also be submitted to NDA and will be made freely available.

Supporting information: Study protocol

Time frame: Data will be deposited starting 18 months after the award begins and will be deposited every six months thereafter following the usual NDA data submission dates. Data generated from this project will be made available as soon as possible, and no later than the time of publication or the end of the funding period, whichever comes first. The duration of preservation and sharing of the data is controlled by the NDA; NDA currently has no process for deleting or retiring datasets, and thus far no data has been removed to our knowledge.

Access criteria: To request access to the data, researchers can use the standard processes at NDA; the NDA Data Access Committee will review requests and decide which requests to grant. The standard NDA access process allows access for one year and is renewable thereafter.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2028, 28 months later.

Of 1,064 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 28 months is below that.

Counting every sponsor, half of 1,092 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 18, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Feb 28, 2029
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07656545
Collaborators
Los Angeles General Medical Center, National Institute of Mental Health (NIMH)
Responsible party
Sponsor
First posted
Jun 18, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Jun 18, 2026

Study contacts

Sarah Stoycos, PhD
Contact
sarah.stoycos@med.usc.edu
323-409-7621
Sarah Stoycos, PhD
principal investigator · University of Southern California, Keck School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion